Abstract: Objective: To compare the efficacy and toxicity of HCPT between radiosensitive agents with conventional radiotherapy (RT) and conventional RT alone. Methods: Sixty patients with stage NSCLC were divided randomly into two groups, i.e. the experiment group and the controls. In the ex-perimental group, all patients were treated by conventional fractional radiotherapy with a total dose of 60-70Gy/30-35f/6-7w. HCPT (8mg/m 2 ) was given intravenously with NS 500ml within an hour after theRT, twice a week for 6 to 7 weeks and chemotherapy of HP(HCPT+DDP) was given for 4 cycles. In the Contrast group, all patients were given to a total dose of 60-70Gy with conventional RT. Results: The short-term overall response rate and the 1-year locoregional control rate, as well as survival rate of the experimental group were significantly higher compared to the controls. The 1-year distant metastasis rate of the experimental group much lower than that of the contrast group, and there was a significant difference between the 2 groups (P<0.05). The more common side-effects were myelosuppression andthe symptom of gastrointestinal tract in the experimental group was much higher compared to the con-trol. There was a significant difference between the 2 groups (P<0.05). But most of the reactions in ex-periment group were grade and, and there was no impact on the treatment. Conclusion: HCPT, as ra-diosensitivity agent plus radiotherapy, is safe and effective for local advanced NSCLC. It is worthy ofdoing further clinical investigation.